Management and Treatment of Perianal Fistulizing Crohn’s Disease
Joseph J Lee,1â 4 Amy L Lightner1,3,4 1Department of Colorectal Surgery, Scripps Clinic, La Jolla, CA, USA; 2Naval Medical Center San Diego, Department of Surgery, San Diego, CA, USA; 3Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA, USA; 4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USACorrespondence: Amy L Lightner, Email [email protected]: Perianal fistulizing Crohnâs disease is a severe and disabling phenotype of Crohnâs disease, affecting up to one-third of Crohnâs patients. This phenotype can result in significant quality of life impairment in quality of life due to chronic pain, persistent perianal drainage, and the risk of fecal incontinence. The presence of a perianal fistula indicates a more aggressive disease course, often requiring more frequent and coordinated care. Optimal management relies on a multidisciplinary team, including gastroenterologists, colorectal surgeons, and radiologists, to address the complex interplay of medical and surgical needs. Medical therapy achieves durable remission in only about one-third of patients, necessitating surgical intervention for the majority, with patients arriving to the operating room with more advanced disease activity and longer duration of immunosuppression. For patients with refractory disease, mesenchymal stem cell (MSC) therapy has emerged as a promising option, with clinical remission rates of approximately 50â 80% at 6â 12 months and a favorable safety profile, notably without increasing the risk of incontinence compared to conventional surgery. However, there is no approved MSC product currently available for clinical use. Given the complexity and morbidity of fistulizing perianal Crohnâs disease, a multidisciplinary approach focused on individualized, evidence-based therapy is essential for optimizing outcomes.Keywords: perianal Crohnâs disease, perianal fistula, mesenchymal stem cell therapy, perianal surgery
Publication Details
- Journal
- Dove Medical Press (Taylor and Francis Group)
- Published
- 2025-12-13
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00